Development and Validation of RP-LC Method for Linezolid in Pharmaceutical Formulations

International Journal of Applied Chemistry

© 2022 by SSRG - IJAC Journal

Volume 9 Issue 1

Year of Publication : 2022

Authors : Syed Mastan Ali, Ponnuri Bharath, V. Siva Ramakrishna, D. Ramachandran

10.14445/23939133/IJAC-V9I1P103

How to Cite?

Syed Mastan Ali, Ponnuri Bharath, V. Siva Ramakrishna, D. Ramachandran, "Development and Validation of RP-LC Method for Linezolid in Pharmaceutical Formulations," SSRG International Journal of Applied Chemistry, vol. 9,  no. 1, pp. 18-24, 2022. Crossref, https://doi.org/10.14445/23939133/IJAC-V9I1P103

Abstract:

A new, simple, rapid, selective, precise and accurate isocratic reverse-phase high-performance liquid Chromatography assay method has been developed to estimate Linezolid in tablet formulations. The separation was achieved using column Inert sustain C18 (250×4.6 mm, 5μ) in the mobile phase consisting of methanol and pH 3.0 phosphate buffer in the ratio of (45:55, v/v). The flow rate was 1.0 mL/min-1, and the separated Linezolid was detected using a UV detector at 251 nm. Column temperature 45°C and sample temperature ambient and injection volume 20 μL. The retention time of Linezolid was noted to be 4.95 min, respectively, indicative of a rather shorter analysis time. The method was validated as per ICH guidelines. The proposed method was found to be accurate, reproducible, and consistent.

Keywords:

Liquid Chromatography, Linezolid, Validation.

References:

[1] Zurenko G. E, Gibson J. K, Shinabarger D. L, Aristoff P. A, Ford C.W, Tarpley W. G, Novel Oxazolidinone–Quinolone Hybrid Antimicrobials. Curr. Opin. C. Pharmacol. 1 (2001) 470–476.
[2] Brickner S. J, Oxazolidinone Antibacterial Agents. Curr. Pharm. Des. 2 (1996) 175–194.
[3] Xu G. Y, Zhou Y, Xu M. C, A Convenient Synthesis of Antibacterial Linezolid from (S)-Glyceraldehyde Acetonide. Chin. Chem. Lett. 17 (2006) 302–304.
[4] Silva P. S. L, Neto H. M, Sejas L. M, Development and Validation of an Agar Diffusion Assay Stability-Indicating to Determination of the Potency of Linezolid in Tablets in the Presence of Photodegradation Products. Braz. J. Infect. Dis. 11 (2007) 297–299.
[5] Reis A. O, Cordeiro J. C. R, Machado A. M. O, Sader H. S, Determination of Linezolid and its Achiral Impurities Using Sweeping Preconcentration by Micellar Capillary Electrophoresis. Braz. J. Infect. Dis. 5 (2001) 243–251.
[6] Abb J, Bacterial Infection Following Refractive Surgery. Diagn. Microbiol. Infect. Dis. 43 (2002) 319–321.
[7] Patel R, Rouse M. S, Piper K. E, Steckelberg J. M, Diagn. Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis. Microbiol. Infect. Dis. 34 (1999) 119–122.
[8] Wilson A. P, Cepeda J. A, Hayman S, Whitehouse T, Singer M, Bellingan G, In vitro Susceptibility of Gram-Positive Pathogens to Linezolid and Teicoplanin and Effect on Outcome in Critically Ill Patients. J. Antimicrob. Chemother. 58 (2006) 470–473.
[9] Ba B. B, Binso B. B, Quentin C, Saux M. C, Determination of Linezolid in Growth Media by High-Performance Liquid Chromatography with On-Line Extraction. J. Chromatogr. B. 854 (2007) 104–108.
[10] Buerger C, Joukhadar C, Muller M. M, Kloft C, Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. J. Chromatogr. B. 796 (2003) 155–164.
[11] Tobin C. M, Sunderland J, White L. O, MacGowan A. P, Ventriculitis Due to a Hetero Strain of Vancomycin Intermediate Staphylococcus aureus (hVISA) Successful Treatment with Linezolid in Combination with Intraventricular Vancomycin. J. Antimicrob. Chemother. 48 (2001) 605–608.
[12] Borner K, Borner E, Lode E. H, Inter. Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple Doses. J. Antimicrob. Agents. 18 (2001) 253–264.
[13] Stefanie S, Michael O, Konstantinos A, Heinrich K. G, Markus A. W, Torsten H. T, A Simple Isocratic HPLC Assay to Determine Linezolid Concentrations in Different Biomatrices for In vivo and In vitro Studies. J. Chem. Lab Med. 45 (2007) 1019–1022.
[14] Boak L. M, Jian L, Nation R. L, Rayne C. R, High-Performance Liquid Chromatographic Method for Simple and Rapid Determination of Linezolid in Human Plasma. J. Biomed. Chrom. 20 (2005) 782–786.
[15] Tobin C. M, Sunderland J, Lovering A. M, MacGowan A. P, A High-Performance Liquid Chromatography (HPLC) Assay for Linezolid in Continuous Ambulatory Peritoneal Dialysis Fluid (CAPDF). J. Antimicrob. Chemother. 51 (2003) 1041–1042.
[16] Cavazos-Rocha N, Vera-Cabrera L, Welsh-Lozano O, Waksman-De-Torres N, Salazar-Cavazos M. L, Simultaneous Determination and Validation of Antimicrobials in Plasma and Tissue of Actinomycetoma by High-Performance Liquid Chromatography with Diode Array and Fluorescence Detection. J. Pharm. Biomed. Anal. 43 (2007) 1775–1781.
[17] Bebaway L. I, Spectrophotometric and HPLC Determination of Linezolid in the presence of Its Alkaline-Induced Degradation Products and Pharmaceutical Tablets. Anal. Lett. 36 (2003) 1141–1161.
[18] Lopes C. C. G. O, Salgado H. R. N, Development and Validation of an Agar Diffusion Assay Stability-Indicating to Determination of the Potency of Linezolid in Tablets in the Presence of Photodegradation Products. Chromatographia. 69 (2009) S129–S135.
[19] Reddy K. V. S. R, Rao M. S, Reddy O. G, Suresh T, Moses Babu J, Dubey P. K, Vyas K, Isolation and Characterization of process-related Impurities in Linezolid. J. Pharm. Biomed. Anal. 30 (2002) 635–642.
[20] Michalska K, Pajchel G, Tyski S, Determination of Linezolid and Its Achiral Impurities Using Sweeping Preconcentration by Micellar Capillary Electrophoresis. J. Pharm. Biomed. Anal. 48 (2008) 321–330.
[21] Bebaway L. I, Spectrophotometric and HPLC Determination of Linezolid in the presence of its Alkaline-Induced Degradation Products and Pharmaceutical Tablets. Anal. Lett. Talanta. 60 (2003) 945–954.
[22] Agrawal H, Mahadik K. R, Paradkar A. R, Kaul N, Stability Indicating HPTLC Determination of Linezolid as Bulk Drug and in Pharmaceutical Dosage Form. J. Med. Econ. 29 (2003) 1119–1126.
[23] ICH, Stability Testing of New Drug Substances and Products (Q1AR2), ICH Harmonised Tripartite Guideline, ICH: Geneva. (2003).